Twist, Serimmune identify SARS-CoV-2 antibody therapies

By The Science Advisory Board staff writers

Twist Bioscience has joined forces with Serimmune to identify and evaluate SARS-CoV-2 therapeutic antibody candidates.

Existing Twist antibody candidates that bind with high affinity to either the SARS-CoV-2 S1 spike protein or the human angiotensin-converting enzyme 2 (ACE2) cellular receptor will be evaluated using Serimmune's Serum Epitope Repertoire Analysis (SERA) platforms. Those epitopes that are identified in the first phase of the collaboration will then be used to rescreen Twist's proprietary synthetic antibody discovery libraries to identify and evaluate new candidates, while also further increasing the specificity of antibody candidates, according to the companies.

Copyright © 2020

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking